Published 2026-08-05
Summary: Procter & Gamble (P&G) is reported to have won the bid to acquire Thorne, a supplement maker, in a deal valued at $3.8 billion in cash from L Catterton. An official announcement was expected to follow later on Tuesday.
What We Know
- P&G is acquiring Thorne for $3.8 billion in cash from L Catterton, according to multiple sources.
- The purchase price for the Thorne deal is reported as $3.8 billion.
- The deal involves a private-equity owner related to LVMH-backed firm L Catterton, based on the reported source of funds.
- Public statements from executives indicated the acquisition would be announced on the referenced Tuesday, with coverage from Reuters and CNBC corroborating the value and intent.
What’s Still Unclear
- Whether the deal has officially closed or remains subject to regulatory approvals and customary closing conditions as of the available information.
- Specific terms beyond the cash value, such as any regulatory conditions, timing of integration, or strategic objectives beyond the general wellness/health brand expansion implied by the deal.
- Any details about post-deal leadership, brand positioning, or product strategy for Thorne within P&G’s portfolio.
Context
In the consumer health and wellness sector, mergers and acquisitions activity has included strategic moves by large consumer goods companies to expand into personalized health, supplements, and wellness brands. Thorne has positioned itself as a science-backed wellness brand, and P&G has sought to broaden its health and wellness offerings through targeted acquisitions.
Why It Matters
The acquisition would give P&G a larger footprint in the supplements and wellness space, potentially impacting competition, consumer access to Thorne’s products, and the strategic trajectory of both companies in the health-focused consumer market.
What to Watch Next
- Official confirmation and closing details from P&G and Thorne authorities.
- Regulatory review outcomes and any required approvals in major markets.
- Post-acquisition integration plans, including branding and channel strategy for Thorne products.
FAQ
Q: What is the reported acquisition price for Thorne?
A: $3.8 billion in cash.
Q: Who is selling Thorne to P&G?
A: L Catterton, the private-equity owner backed by LVMH.
Related coverage
- Profit forecast upgrade obesity diabetes drug sales rises
- SpaceX revenue exceeds expectations surges post-IPO
- BP diversify investor perception: O’Neill aims to reverse
Source Transparency
- This article is based on a short preliminary brief and may not reflect the full details available in ongoing reporting.
- Source links are provided in the Sources section where available.
- A limited open-web check was used to clarify key details when possible; unclear items remain clearly marked.
Original brief: Procter & Gamble appears to have won the bidding war for supplement maker Thorne with a deal worth $3.8 billion set to be announced later Tuesday…
Sources
- P&G buys supplements maker Thorne for $3.8 billion as wellness push …
- Procter & Gamble to buy Thorne for $3.8 billion, CEO tells CNBC
- Thorne Enters into Definitive Agreement to Be Acquired by Procter & Gamble
- Procter & Gamble to Acquire Thorne for $3.8B, Expanding Personal Health …
- P&G to Buy Supplement Maker Thorne for $3.8 Billion | BoF